PharmaEssentia surpasses enrollment goals in clinical trials for hematology candidate BESREMi
PharmaEssentia USA Corporation, a key player in biopharmaceutical innovation and a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced a significant milestone in the development of its drug, ropeginterferon alfa-2b-njft (BESREMi). The company has successfully completed enrollment for two pivotal clinical trials, exceeding initial targets in both cases, which aim to expand treatment options in hematology, […]